Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology - Biogen

Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology  BiogenBiogen to buy Apellis Pharmaceuticals for $5.6 billion in rare disease push  CNBCBiogen to Buy Apellis for $5.6 Billion to Boost Kidney Franchise  Bloomberg.comBiogen will acquire a drug company for $5.6 billion to expand work in kidney diseases  MarketWatchBiogen to acquire immunology biotech Apellis for $5.6 billion  The Boston Globe